Yüklüyor......
HER2 in Breast Cancer Stemness: A Negative Feedback Loop towards Trastuzumab Resistance
HER2 receptor tyrosine kinase that is overexpressed in approximately 20% of all breast cancers (BCs) is a poor prognosis factor and a precious target for BC therapy. Trastuzumab is approved by FDA to specifically target HER2 for treating HER2+ BC. However, about 60% of patients with HER2+ breast tum...
Kaydedildi:
| Yayımlandı: | Cancers (Basel) |
|---|---|
| Asıl Yazarlar: | , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
MDPI
2017
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5447950/ https://ncbi.nlm.nih.gov/pubmed/28445439 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers9050040 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|